Interferon alpha-2: Clinical Trials

68 trials of Interferon alpha-2, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

44 completed, 13 terminated, 7 unknown, 2 withdrawn. 68 Phase 2, 11 Phase 1, 7 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 268Completed 44, Terminated 13, Unknown 7, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1
Phase 111Completed 5, Terminated 3, Unknown 2, Withdrawn 1
Phase 37Completed 4, Terminated 2, Unknown 1

Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer
Phase 2Not yet recruitingKalinski, Pawel, MD, PhD282026-10-012026-10-13
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma
Phase 2TerminatedRoswell Park Cancer Institute12024-11-132026-02-25
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute52024-02-162026-08-31
Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients
Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute42020-11-172026-01-13
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Phase 2Active not recruitingRoswell Park Cancer Institute122019-11-292026-06-09
Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin - Ovarian Cancer Recurrent
Phase 1 / Phase 2UnknownLeiden University Medical Center122018-08-012021-04-01
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma
Phase 2CompletedRoswell Park Cancer Institute192018-04-192022-03-02
Interferon-α After DLI for the Prevention of Relapse
Interferon Alfa-2b - Leukemia
Phase 1 / Phase 2UnknownPeking University People's Hospital422015-12-012016-09-29
Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
TG-2349, Ribavirin, Interferon Alfa-2a - Hepatitis C, Chronic
Phase 2CompletedTaiGen Biotechnology Co., Ltd.252015-05-012023-07-14
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
DC vaccine, Celecoxib, Interferon Alfa-2b - Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma
Phase 1 / Phase 2CompletedDavid Bartlett642014-07-012020-07-20
Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients
Human Serum ALbumin/interferon alpha2a, Pegasys - Chronic Hepatitis B
Phase 1 / Phase 2CompletedBeijing Bio-Fortune Ltd.322013-11-012014-11-17
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7
Phase 2CompletedNational Cancer Institute (NCI)882013-03-252026-07-21
Sequential Therapy in Metastatic Renal Cell Carinoma
Avastin in combination with Roferon-A, Afinitor, TKI: Sutent, Nexavar or Votrient - Metastatic Renal Cell Carcinoma
Phase 2CompletedCentral European Society for Anticancer Drug Research222012-10-012019-02-06
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma
Phase 1 / Phase 2TerminatedRoswell Park Cancer Institute152012-10-012023-10-27
Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer
Interferon Alfa-2b, p53 SLP - Recurrent Ovarian Cancer
Phase 1 / Phase 2CompletedLeiden University Medical Center152011-08-012014-01-07
Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma
Pazopanib + interferon alpha 2A - Advanced Renal Cell Carcinoma
Phase 1 / Phase 2CompletedSpanish Oncology Genito-Urinary Group532011-07-112022-03-10
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Interferon (IFNα, Roferon-A) - Chronic Lymphocytic Leukemia
Phase 1 / Phase 2WithdrawnM.D. Anderson Cancer Center2011-04-012012-08-03
Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
lovastatin, interferon alfa-2b - Melanoma, Malignant Melanoma
Phase 2WithdrawnNeoPlas Innovation2502009-12-012009-09-09
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Phase 2CompletedCase Comprehensive Cancer Center382009-11-112019-02-26
Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer
Interleukin-2, Interferon Alfa-2b, Bevacizumab - Metastatic Renal Cell Carcinoma
Phase 2UnknownUniversity of Aarhus1182009-10-012014-12-02

Showing 20 of 68. Sign in to see all of them.

Conditions studied

Carcinoma, Renal Cell (14)  ·  Melanoma (10)  ·  HIV Infections (6)  ·  Hepatitis C (4)  ·  Hepatitis C, Chronic (4)  ·  Leukemia (4)  ·  Acquired Immunodeficiency Syndrome (3)  ·  Hematologic Neoplasms (3)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3)  ·  Neoplasm Metastasis (3)  ·  Neoplasms (3)  ·  Brain Neoplasms (2)  ·  Colorectal Neoplasms (2)  ·  Hepatitis B, Chronic (2)  ·  Kidney Neoplasms (2)

Sponsors

M.D. Anderson Cancer Center (10)  ·  National Cancer Institute (NCI) (8)  ·  Roswell Park Cancer Institute (6)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Hoffmann-La Roche (3)  ·  Merck Sharp & Dohme LLC (3)  ·  Case Comprehensive Cancer Center (2)  ·  Leiden University Medical Center (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Beijing Bio-Fortune Ltd. (1)  ·  Central European Society for Anticancer Drug Research (1)  ·  Centre Leon Berard (1)  ·  Children's Oncology Group (1)  ·  Dartmouth-Hitchcock Medical Center (1)  ·  David Bartlett (1)

Countries

United States (41)  ·  Germany (5)  ·  Netherlands (5)  ·  Switzerland (5)  ·  France (4)  ·  Spain (4)  ·  United Kingdom (4)  ·  Canada (3)  ·  Italy (3)  ·  Puerto Rico (3)  ·  Russia (3)  ·  China (2)  ·  Czechia (2)  ·  Finland (2)  ·  Hungary (2)

Top investigators

Igor Puzanov (2)  ·  Ahmad Tarhini (1)  ·  Amar Safdar, MD (1)  ·  Amer H Zureikat, MD (1)  ·  Ana M. Aparicio, MD (1)  ·  Anas Younes, MD (1)  ·  Andrew Muir, M.D. (1)  ·  Brian Rini (1)  ·  Daniel George (1)  ·  David L Bartlett, MD (1)  ·  Ellis Levine, MD (1)

Results publications

PMID 37146227, PMID 15079763, PMID 15282352, PMID 15563253, PMID 15685543, PMID 15867490, PMID 16115185, PMID 16439867, PMID 19622576, PMID 20622678, PMID 21664867, PMID 23803225, PMID 25851632, PMID 25900027, PMID 27101285, PMID 28291640, PMID 28620382, PMID 29152412, PMID 29392960, PMID 29563634, PMID 29774030, PMID 31371315, PMID 34327591, PMID 36848607

NIH funding

P30CA016672 (4), P01CA234212 (3), 2004 (1), 2008 (1), N01CM17101 (1), N01CM62202 (1), P01CA132714 (1), P30CA016056 (1), P30CA023108 (1), P30CA072720 (1), R01AI049141 (1), R01CA095648 (1), U01CA070172 (1), U01CA099118 (1), U10CA021115 (1)